Clinical trial
Trial of Carboplatin/Paclitaxel/Cetuximab in Stage IIIB/IV Non-Small Cell Lung…
NCT00097227 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00097227 |
|---|---|
| Title | Trial of Carboplatin/Paclitaxel/Cetuximab in Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC) |
| Official title | A Randomized Phase II Trial of Two Dose Schedules of Carboplatin/Paclitaxel/Cetuximab in Stage IIIB/IV Non-small Cell Lung Cancer |
| Lead sponsor | Eli Lilly and Company, Industry |
| Collaborators | Bristol-Myers Squibb Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Non-small Cell Lung Cancer |
| Intervention type | Biological, Drug |
| Interventions | Cetuximab, Carboplatin, Paclitaxel |
| Enrollment | 165 |
| Start date | Nov 1, 2004 |
| Primary completion | Apr 1, 2007 |
| Completion | Apr 1, 2007 |
| First posted | Nov 19, 2004 |
| Last update posted | Apr 9, 2010 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: